Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.

IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical functioning over 24 months in methotrexate (MTX)-naive adult patients with RA. In this post hoc analysis, we compared efficacy and safety of tofacitinib in patients with early (disease duration <1 year) versus established (≥1 year) RA.MethodsMTX-naive patients ≥18 years with active RA received tofacitinib monotherapy (5 or 10 mg two times a day, or MTX monotherapy, in a 24-month Phase 3 trial.ResultsOf 956 patients (tofacitinib 5 mg two times a day, n=373; tofacitinib 10 mg two times a day, n=397; MTX, n=186), 54% had early RA. Baseline disease activity and functional disability were similar in both groups; radiographic damage was greater in patients with established RA. At month 24, clinical response rates were significantly greater in patients with early versus established RA in the tofacitinib 5 mg two times a day group. Both tofacitinib doses had greater effects on clinical, functional and radiographic improvements at 1 and 2 years compared with MTX, independent of disease duration. No new safety signals were observed.ConclusionsTreatment response was generally similar in early and established RA; significantly greater improvements were observed at month 24 with tofacitinib 5 mg two times a day in early versus established RA. Tofacitinib 5 and 10 mg two times a day demonstrated greater efficacy versus MTX irrespective of disease duration. No difference in safety profiles was observed between patients with early or established RA.Trial registration numberNCT01039688; Results

Implementatie van gepersonaliseerd beweegprogramma bij patiënten na kanker

Bewegen is gezond, ook voor patiënten die kanker hebben gehad. Helaas beweegt het merendeel van deze patiënten nog onvoldoende. Leefstijlbegeleiding in de eerste lijn zou veel patiënten kunnen bereiken. Daarom bekijkt de afdeling Huisartsgeneeskunde en Ouderengeneeskunde van het UMC Groningen de implementatie van een laagdrempelig en gepersonaliseerd beweegprogramma in de huisartsenpraktijk: het SoDA-onderzoek (Stimulation of Daily Activities)

Dynamics and Asymetric Adjustment in Insider-Outsider Models

efficiency ; employment ; contracts ; economic equilibrium

The AARTFAAC 60 MHz transients survey

We report the experimental setup and overall results of the AARTFAAC wide-field radio survey, which consists of observing the sky within 50$^\circ$ of Zenith, with a bandwidth of 3.2$\,$MHz, at a cadence of 1$\,$s, for 545$\,$h. This yielded nearly 4 million snapshots, two per second, of on average 4800 square degrees and a sensitivity of around 60$\,$Jy. We find two populations of transient events, one originating from PSR$\,$B0950$+$08 and one from strong ionospheric lensing events, as well as a single strong candidate for an extragalactic transient, with a peak flux density of $80\pm30$$\,$Jy and a dispersion measure of $73\pm3\,\mathrm{~pc~cm^{-3}}$, We also set a strong upper limit of 1.1 all-sky per day to the rate of any other populations of fast, bright transients. Lastly, we constrain some previously detected types of transient sources by comparing our detections and limits with other low-frequency radio transient surveys.Comment: 10 pages, 8 figures. Published by MNRA

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis

PMCID: PMC3856490This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.PMCID: PMC385649